All eyes are on Kevin Warsh. The new Fed chair delivers his first rate decision today (2pm ET / 8pm Rome), and after Monday’s US–Iran-deal surge the tape is already second-guessing the path. Tuesday split three ways: the Dow eked out a record (+0.64%, just shy of 52,000) while the Nasdaq slid 1.15% in a tech pullback and the S&P finished flat (−0.08% at ~7,549). Crude kept deflating — Brent under $80, WTI near $75, a three-to-four-month low — as the Strait of Hormuz reopening nears and an official US–Iran signing looms. The BOJ hiked to a 31-year-high 1.00% on Tuesday, the dollar is bid on a revived “US exceptionalism” trade, and the 10-year eased to 4.43%. Markets price a hold at 3.50–3.75% (~97% odds) but expect Warsh to drop the easing bias with inflation near a three-year high — making the dot plot and his debut press conference the real event.
Snapshot is Tuesday 16 June’s US/UK closes from the live Bloomberg ticker read this morning; the S&P level is cross-checked to Tuesday’s official close. The 10-year, FX, crude and gold reflect the live overnight move. The week’s swing factor is today’s Warsh Fed decision (8pm Rome) and dot plot; the US–Iran signing and Hormuz reopening logistics frame the rest, with a Juneteenth US market close on Friday.
Top of the morning
Warsh’s first Fed decision lands today — a hold, but watch the bias and the dots
The FOMC concludes its two-day meeting at 2pm ET (8pm Rome), Kevin Warsh’s debut as chair after succeeding Powell last month. Futures put ~97% odds on no change, leaving the range at 3.50–3.75%, so the story is everything around the number: economists expect the statement to scrap its prior easing bias for a neutral stance, with inflation running near a three-year high of ~3.8–4.2%. The fresh dot plot, the new chair’s inaugural press conference, and a widening gap between market pricing and the Fed’s last projections are the real signals.
Markets consolidate after the deal surge: Dow at a record, but tech gives back ground
Monday’s US–Iran-deal rally (S&P +1.65%) gave way to a split tape Tuesday. The Dow rose 0.64% to a record just shy of 52,000, while the Nasdaq slid 1.15% as chip and megacap-tech names cooled and the S&P closed essentially flat. The rotation reads as profit-taking into the Fed rather than a change of trend; strategists keep warning the Iran deal is more a trading catalyst than the start of a durable leg, with Tehran’s nuclear file and sanctions scope still unresolved.
Oil slides toward a glut as Hormuz reopening nears and the signing approaches
Brent fell below $80 for the first time in over four months and WTI sat near $75 — a multi-month low — as traders price out the war premium on bets that Strait of Hormuz flows return. Qatar is moving LNG ships back toward the Mideast and Iran is repositioning tankers ahead of an expected signing; a 14-point draft memorandum would hand Tehran broad financial incentives, including access to a $300bn development fund tied to “performance.” FT’s Lex now frames the risk as a coming glut rather than a shortage, though normalising physical flows could still take weeks.
BOJ raises rates to a 31-year high of 1.00% as global normalisation rolls on
The Bank of Japan lifted its overnight rate 25bp to 1.00% on Tuesday — the highest since 1995 — citing a weak yen and inflation stoked partly by the Iran energy shock; it was the first move since December. Markets took it in stride: yen volatility sits at its lowest since 2021, and the BOJ kept guidance gradual. The hike, landing the day before the Fed, underlines a world of central banks edging away from ultra-easy policy even as growth signals soften.
The AI-financing machine keeps roaring — increasingly on borrowed money
Nvidia is raising over $25bn in its first bond deal since 2021, the latest test of appetite amid an AI-sector borrowing deluge; Bain Capital stands to bank a ~$15bn windfall on its Kioxia chip bet; and Huawei’s comeback is testing the limits of US chip controls. SpaceX, days after its record IPO, leapfrogged Amazon to become the world’s fifth-most-valuable company and struck a $60bn deal for AI coding app Cursor. Schroders’ CIO insists this isn’t “a bubble,” but the funding mix — bonds and private credit over cash flow — is the thing to watch.
G7 leaders agreed to raise pressure on Moscow “notably” through new limits on oil and gas exports, even as the broader mood is de-escalation around the Iran deal. Putin is hosting his first Southeast Asia summit since the Ukraine invasion, a bid to show he isn’t isolated, and a Russian warship fired warning shots near a British yacht in the English Channel (the UK says it is unrelated to its interception of a shadow-fleet tanker). The EU has opened membership talks with Ukraine after Hungary’s new leadership dropped its veto.
Macro & credit watch: hot import prices, private-credit jitters, a softer China
US import prices rose the most in nearly four years (war plus the AI boom), a reminder that the inflation backdrop into Warsh’s Fed is sticky. Beneath the indices, credit shows strain: UK wealth manager Rathbones fell 18% after halting investments for high-risk clients, DE Shaw is closing a $5bn fund to new money, and Man Group flags “bubble risks” as AI-linked bond sales break records. China’s May data disappointed — retail sales fell for the first time in over three years — and BMW cut profit guidance, partly on its Chinese market.
FT portfolio signal · tied to your holdings
What FT flagged for your book
Macro / regime read. FT’s feed sketches a constructive-but-watchful regime. The energy shock is unwinding fast — FT’s Lex argues “the oil shortage is ending and the glut is coming,’’ with Brent back under $80 — which drains the stagflation tail and is risk-supportive; the offset is that G7 just agreed to tighten Russian-energy sanctions, a two-way supply wildcard, and FT cautions the “long way back” from the shock takes months. On rates, FT’s lead is the return of the “US exceptionalism” trade: investors are piling into bullish dollar bets on the view a buoyant US economy keeps the Fed from cutting even as oil falls — higher-for-longer, stronger dollar, duration caution into today’s dot plot. The clearest regime flag for your war-chest discipline is credit/AI-capex froth: Nvidia’s $25bn bond and a record AI-linked issuance wave, the Bain–Kioxia windfall, and pockets of private-credit stress (Rathbones −18%, a DE Shaw fund closing). No fresh severe trigger — so war-chest deployment rules stay sheathed — but the mix keeps the stance neutral-to-defensive.
AI capex & semiconductors (theme — your semis/cloud shelf) · read-through to ASML, Broadcom, Microsoft, Alphabet, Amazon. The compute build still looks voracious — Nvidia’s debt deal, Bain’s ~$15bn on Kioxia, Amazon backing “world-model” start-up Odyssey (alongside Nvidia and AMD), HSBC claiming $100m+ of gains from Google AI tools — but it is leaning on bonds and private credit. Watch-item for the moat: FT’s report that Huawei’s advances appear to sidestep US export curbs, a slow-burn risk to the ASML/Broadcom export-control thesis.
AI policy / Anthropic overhang (theme). FT reports the US and Europe are discussing a “trusted partner” scheme for access to top AI models after the White House’s curbs on Anthropic, which FT calls “capricious.’’ Not a held single name, but a sentiment/regulatory overhang on the whole AI complex your cloud and semis names ride.
Payments (Visa, Mastercard) · slow-burn risk. Bloomberg’s Markets cover (cross-read) has Europe pushing for “payment sovereignty’’ and alternatives to the US card networks, echoing China’s cross-border digital-payments drive. No near-term catalyst, but a structural watch-item for the network duopoly.
Healthcare / GLP-1 (Novo Nordisk, Eli Lilly) · quiet in FT, live in the clinical desk. No FT single-name items on Novo, Lilly, UnitedHealth, Vertex, Thermo Fisher or Intuitive today — but see the clinical desk below for the maturing oral-GLP-1 data (Lilly’s orforglipron), which keeps the obesity-franchise theme firmly intact.
Industrials / defence (Caterpillar, Deere) · mixed. A GM–Lockheed munitions tie-up and G7 defence-spending momentum are a capex tailwind, but China’s soft May data and BMW’s guidance cut flag a demand drag for global-cyclical machinery exposure.
Shelf single-names live today: none as standalone catalysts — the actionable read stays theme-level: durable AI-compute demand (semis/cloud) set against a hawkish-leaning Warsh Fed, an oil slide FT thinks turns into a glut, and a credit/private-credit froth flag.
Net: the relief rally has substance — a real deal and crude at a multi-month low ease the stagflation tail — but a strong-dollar / higher-for-longer rates tilt into Warsh’s first Fed and visible AI-credit froth keep the regime neutral-to-defensive. No severe trigger, so war-chest rules stay sheathed. Watch-lines: today’s Fed & dot plot, the US–Iran signing and Hormuz logistics, China stimulus signals, and AI-sector bond / private-credit supply.
Markets snapshot
Read this morning from the live Bloomberg “Top Securities” ticker. Equity indices are Tuesday 16 June US/UK closes; the 10-year, FX, crude and gold show the live overnight move. The S&P level is cross-checked to Tuesday’s official close; the Dow notched a record (+0.64%, just shy of 52,000).
Instrument
Last
Move / context
S&P 500
7,548.60
−0.08% · Tue close; flat as tech slips, Dow at record
Nasdaq Composite
26,376.34
−1.15% · Tue close; megacap/chip pullback
FTSE 100
10,494.21
+0.61% · Tue close; defensives lead
US 10-year Treasury
4.43%
−3bp · yields ease into Warsh’s Fed
EUR/USD
1.16
dollar bid · “US exceptionalism” trade returns
GBP/USD
1.34
steady
Crude Oil (WTI)
$75.40
multi-month low · Brent <$80 as Hormuz reopening nears
Gold (spot)
$4,353
holds gains near record
Levels transcribed from the Bloomberg Europe ticker this morning, with the S&P close cross-checked to ~7,549 (−0.08%) given a ticker-tile discrepancy. The day’s standout was the Dow’s record close just shy of 52,000 even as the Nasdaq fell — a rotation into the Fed. Crude near a multi-month low, gold firm near record, yields a touch lower. Next catalysts: today’s Warsh Fed, the US–Iran signing, and the Hormuz reopening.
Global markets & macro
The market’s pivot point is Kevin Warsh. His first FOMC decision arrives this afternoon (2pm ET / 8pm Rome) with a near-certain hold at 3.50–3.75%, so attention falls on the language and the projections: the statement is widely expected to retire its easing bias for a neutral stance, and a dot plot drawn against ~4% inflation could sit well above where markets are pricing cuts. Tuesday’s tape already leaned cautious — the Dow squeezed out a record while the Nasdaq fell 1.15% as megacap and chip names gave back some of Monday’s US–Iran-deal surge, and the S&P finished flat. The BOJ’s 25bp hike to a 31-year-high 1.00% added to the higher-for-longer tone, yet yen volatility sits at its calmest since 2021. The dollar is firm on a revived “US exceptionalism” trade, the 10-year eased to ~4.43%, and crude kept sliding — Brent below $80, WTI near $75 — as the war premium drains toward what FT now calls a coming glut.
Above the macro, the capital-markets plumbing keeps rewriting itself, and increasingly on credit. Nvidia is selling more than $25bn of bonds — its first issue since 2021 — into an AI-borrowing wave that has Man Group warning of “bubble risks,” while Bain Capital is set to bank a ~$15bn windfall on Kioxia and SpaceX has leapfrogged Amazon to fifth-most-valuable company days after its IPO, adding a $60bn Cursor deal. The confidence vote on the buildout is real, but it drains liquidity from listed names and concentrates risk in private credit — where the cracks (Rathbones −18%, a DE Shaw fund closing to new money) are starting to show, even with a record cash pile still parked in money-market funds. China is the other cross-current: May retail sales fell for the first time in over three years and BMW cut guidance on its Chinese business, reviving the case for stimulus and tempering the global-growth read behind cyclicals.
Geopolitics & world news
The Middle East still anchors sentiment, and the direction remains de-escalation with caveats. The US and Iran are preparing to sign an agreement — a 14-point draft memorandum that would reopen the Strait of Hormuz, lift the US maritime blockade and offer Tehran broad financial incentives, including access to a $300bn development fund tied to its “performance.” Qatar is already moving LNG carriers back toward the Gulf and Iran is repositioning its tankers, but restoring normal traffic through Hormuz is the contested part: shipowners want confidence before transiting, and Bloomberg and FT both flag that physical flows could take weeks. Netanyahu, meanwhile, faces a cross-spectrum domestic backlash over a deal critics say lets Iran emerge with leverage intact, and Trump is fielding the charge at home that his terms are worse than the 2015 accord. At the G7, leaders agreed to tighten sanctions on Russian energy “notably,” and Modi arrived warning of a “trust deficit” before meeting Trump.
On the eastern and home fronts, the friction is sharper. The EU formally opened accession talks with Ukraine after Hungary’s new leadership dropped its veto; Putin is hosting his first Southeast Asia summit since the invasion to project that he isn’t isolated; and a Russian warship fired warning shots near a British yacht in the English Channel, days after the UK intercepted a shadow-fleet oil tanker. For the technology-policy reader, the Anthropic saga rolls on — the US and Europe are discussing a “trusted partner” framework for access to frontier AI models after the White House’s export curbs, which FT calls capricious — while France’s foreign-intelligence service is replacing Palantir with a local rival, part of a wider European drive to cut dependence on US tech. The clinical reader’s deep-dive follows below.
Clinical desk · NEJM this week
For the medical reader
Now read from the live NEJM feeds (the bot-check cleared): a cardiology-dominated issue — coronary imaging and physiology, AF ablation, adolescent HCM — alongside landmark gene-editing and cardiorenal readouts. The results, not just the titles.
OPTIMAL — IVUS- vs angiography-guided PCI in unprotected left main disease (neutral). Across 806 patients at 28 high-volume European centres, routine intravascular ultrasound did not beat angiography: the patient-oriented composite of death, MI, stroke or any revascularisation occurred in 33.7% with IVUS vs 30.9% with angiography (HR 1.11; 95% CI 0.87–1.42; p=0.40) at a mean 2.9 years. With the sister IVUS-CHIP trial also neutral in complex high-risk PCI — and two editorials asking whether IVUS is “always necessary” — an angiography-led strategy is defensible in experienced hands. Companion physiology papers (ALL-RISE angiography-derived FFR; FAST III angiography-based physiology) point the same way: wire-free add-ons help selectively, not universally.
AVANT GUARD — pulsed-field ablation as first-line therapy for persistent AF (positive). Randomising 310 patients 2:1 to PFA vs antiarrhythmic drugs with continuous monitoring in all, first-line ablation roughly doubled 12-month success: 56% free of recurrence vs 30% on drugs (composite-failure HR 0.46; 95% CI 0.33–0.65), with serious device/procedure events at 5.1% — under the 12% bar. Extends the first-line-ablation case to persistent, not just paroxysmal, AF (Heart Rhythm 2026).
SCOUT-HCM — mavacamten in adolescents with obstructive HCM (positive; first in teens). In 44 adolescents, the cardiac myosin inhibitor cut the Valsalva LVOT gradient by 48.0 mmHg more than placebo (95% CI −67.7 to −28.3; p<0.0001) over 28 weeks, with secondary endpoints improving and safety mirroring adults. It brings myosin inhibition to a group that previously had only beta-blockers, disopyramide or myectomy (ACC 2026).
VERVE-102 (Heart-2) — in vivo base editing of PCSK9 (first-in-human landmark). A single infusion of an adenine base editor that permanently switches off hepatic PCSK9, given across six doses (0.3–1.0 mg/kg) to adults with heterozygous familial hypercholesterolaemia or premature CAD: mean PCSK9 fell 51–88% and LDL-C 9–62% — a 78 mg/dL absolute LDL drop at the top dose — durable out to ~18 months, with no dose-limiting toxicity (mild-to-moderate infusion reactions, transient ALT rises). A genuine “one-and-done” LDL therapy is moving from concept toward clinic (EAS 2026).
Cardiorenal wins — iptacopan and finerenone. Two positive nephrology readouts with cardiovascular reach. In APPLAUSE-IgAN (final 24-month data, 478 patients), the complement factor-B inhibitor iptacopan slowed eGFR loss (−3.10 vs −6.12 mL/min/1.73m²/yr; difference +3.0) with ~38% less proteinuria and fewer rescue treatments (4.6% vs 13.4%) — a complement-targeted option in IgA nephropathy. In FIND-CKD (>1,500 patients), finerenone slowed eGFR decline over 32 months in non-diabetic CKD and cut a kidney–cardiovascular composite by 23%, pushing the non-steroidal MRA’s label well beyond diabetic kidney disease.
Inhaled treprostinil for IPF — TETON-1 & TETON-2 (positive; a first for the class). Two replicate phase-3 trials had inhaled treprostinil slow 52-week FVC decline versus placebo (placebo-corrected +130.1 mL in TETON-1, +95.6 mL in TETON-2; +111.8 mL pooled), separating by week 8, with fewer clinical-worsening and exacerbation events. The first inhaled prostacyclin shown to modify idiopathic pulmonary fibrosis — a meaningful addition alongside the antifibrotics.
Also in the issue and cardiology feed: survodutide (GLP-1/glucagon dual agonist) up to −16.6% body weight at 76 weeks, with visceral fat down ~34% and liver fat ~63% and muscle largely preserved — the obesity-race read your book tracks via Novo and Lilly; two neutral prehospital whole-blood trials (SWiFT and a US type-O study); a run of critical-care trials (vasopressors vs fluids in early septic shock, balanced fluid vs saline in children, sodium bicarbonate in metabolic acidosis, conservative oxygen after cardiac arrest); in-vivo CRISPR for hereditary angioedema (lonvoguran ziclumeran) and exa-cel in children with β-thalassaemia or sickle cell; myeloma bispecifics (teclistamab; talquetamab–daratumumab); the first reported human H5N5 avian-influenza infection; and a pointed Perspective pair on the hazards of race-based drug dosing.
Provenance: read this morning from Luca’s two pinned NEJM RSS tabs (current-issue eTOC + cardiology / ahead-of-print) via Chrome once the Cloudflare bot-check cleared — issue dated 11 June 2026 plus ahead-of-print. Trial numbers cross-checked against NEJM abstracts and ACC / EAS / Heart Rhythm / ERA 2026 conference coverage (TCTMD, ACC, Healio, Medscape). Summarised, not reproduced verbatim; not clinical advice.
Today & week ahead (CET)
Wed 17Fed decision & dot plot — 8pm Rome (Warsh’s first as chair); hold at 3.50–3.75% expected, easing bias seen dropping; debut press conference ~8:30pm · US May retail sales, industrial production, housing starts
Thu 18Bank of England decision — consensus hold · US weekly jobless claims · FT markets Q&A (Armstrong & Martin, 1pm BST)
Fri 19US stock & bond markets CLOSED — Juneteenth · US–Iran signing ceremony expected; Strait of Hormuz set to reopen — watch oil & tanker-backlog logistics
WatchWarsh’s dot plot & guidance · Hormuz reopening pace & the “glut” call · AI-sector bond / private-credit supply · China stimulus signals · SpaceX (SPCX) follow-through · G7 Russia-energy sanctions